Midostaurin

Chemical formula: C₃₅H₃₀N₄O₄ Molecular mass: 570.649 g/mol PubChem compound: 9829523

Therapeutic indications

Midostaurin is indicated for:

Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation

Population group: only adults (18 - 65 years old)

Midostaurin is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100 mg in 2 divided doses daily

Aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, mast cell leukaemia

Population group: only adults (18 - 65 years old)

Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

200 mg in 2 divided doses daily

Contraindications

Midostaurin is contraindicated in the following cases:

Potent CYP3A4 inducers

Strong potency CYP3A4 inducers

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.